1
MAO INHIBITION AND DEPRESSION-DUNLOP ET AL SUMMARY Intravenous modaline sulfate was evaluated in six hospitalized depressed patients over a three-week course of therapy. The results ob- tained are consistent with the hypothesis that the degree of MAO inhibition is related to clinical improvement of depression. There were no significant side effects noted and no evidence of systemic toxicity due to modaline sulfate therapy. Data presented are prelimi- nary in nature and should be interpreted ac- cordingly. BIBUOGRAPHY 1. Loomer, H. P., Saunders, J. C. and Kline, N. S.: A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Amer. Psychiat. Assoc. Psychiat. Research Rept., 8: 129-135, 1957. 2. Voelkel, A.: Clinical experiences with amine oxidase inhibitors in psychiatry. Ann. N.Y. Acad. Sci., 80:680-686, 1959. 3. Pletscher, A.: Significance of monoamine oxidase inhibition for the pharmacological and clinical effects of hydrazine derivatives. Ann. N.Y. Acad. Sci., 80:1039-1045, 1959. 4. Saunders, J. C., Randinger, N., Rochlin, D. and Kline, N. S.: Treatment of depressed patients with iproniazid and reserpine. Dis. Nerv. Syst., 20( 1) :31-39, 1959. 5. Zeller, E. A.: Some remarks about monoamine oxidase and monoamine oxidase inhibitors. J. Neuropsychiat., 2: 125-130, 1960-1961. 6. Resnick, 0.: The influence of amine oxidase in- hibitors on epinephrine metabolism in man. Ann. N. Y. Acad. Sci., 80:726-733, 1959. 7. Resnick, 0., Hagopian, M., Hoagland, H. and Freeman, H.: An in vivo test for measuring monoamine oxidase inhibition in human subjects. A.M.A. Arch. Gen. Psychiat., 2:459-461, 1960. 8. Feldstein, A., Hoagland, H., Rivera, M. and Freeman, H.: A preliminary report on MAO in- hibition and clinical effectiveness in the treat- ment of depressed patients with phenelzine. ]. Neuropsychiat., 2: 12-14, 1960. 9. Gylys, J. A., Muccia, P. M. R. and Taylor, M. K.: Pharmacological and toxicological properties of 2-methyl-3-piperidinopyrazine, a new antide- pressant. Ann. N. Y. Acad. Sci., 107:899-913, 1963. 10. Dubnick, B., Morgan, F. and Phillips, G. E.: In- hibition of monoamine oxidase by 2-methyl-3- piperidinopyrazine. Ann. N. Y. Acad. Sci., 107: 914-923, 1963. ll. Goldstein, L., Murphree, H. B. and Pfeiffer, C. C.: Quantitative electroencephalography in man as a measure of CNS stimulation. Ann. N. Y. Acad. Sci., 107:1045-1056, 1963. 12. Dunlop, E.: Antidepressant effects of MAO in- hibitors. Ann. N. Y. Acad. Sci., 107:1107-1116, 1963. 13. Feldman, P.: Comparison of effect of 2-methyl- 3-piperidinopyrazine on target symptoms of an- ergic schizophrenics. Ann. N. Y. Acad. Sci., 107:1117-1130, 1963. 14. Hamilton, M.: A rating scale for depression. ]. Neurol. Neurosurg. and Psychiat., 23:56-62, 1960. 15. Sjoerdsma, A., Oates, J. A., Zaltzman, P., and Undenfriend, S.: Identification and assay of urinary tryptamine: application as an index of monoamine oxidase inhibition in man. J. Phar- macol. and Exper. Therap., 126:217-223, 1959. 16. Pisano, J. J., Crout, J. R. and Abraham, D.: Determination of 3-methoxy-4-hydroxymandelic acid in urine. Clin. Chemica. Acta., 7 :285-291, 1962. 17. Undenfriend, S., Titus, E. and Weissbach, H.: The identification of 5-hydroxy-3-indoleacetic acid in normal urine and method for its assay. J.B.C., 216:499-505, 1955. (Doctor Dunlop) Fuller Memorial Sanitarium Attleboro, Massachusetts "The average practitioner is quite capable of handling the vast majority of ex-institutionalized patients by regulation of medication, reassurance, manipulation of the environment where necessary, and ... other technics." -N. S. KLINE, Postgrad. Med., 27:620, May, 1960. ERRATUM In the Editorial of the November-December 1964 issue the editor noted that "Psychoso- matics has now completed its fourth year." This is an understatement of the true facts; since publication was commenced in January, 1960; it is therefore corrected to "its fifth year.' The editor cannot and will not seek refuge in the possibility of an error that can be traced to his assistant, nor to the publisher. The best explanation is either that 1960-1964 is a span of four years, or hopefully that it is a significant slip indicating his continued interest in the journal and the fact that another year or less is not too significant. WD January-February, 1965 .,.

Erratum

Embed Size (px)

Citation preview

Page 1: Erratum

MAO INHIBITION AND DEPRESSION-DUNLOP ET AL

SUMMARY

Intravenous modaline sulfate was evaluatedin six hospitalized depressed patients over athree-week course of therapy. The results ob­tained are consistent with the hypothesis thatthe degree of MAO inhibition is related toclinical improvement of depression. Therewere no significant side effects noted and noevidence of systemic toxicity due to modalinesulfate therapy. Data presented are prelimi­nary in nature and should be interpreted ac­cordingly.

BIBUOGRAPHY

1. Loomer, H. P., Saunders, J. C. and Kline, N. S.:A clinical and pharmacodynamic evaluation ofiproniazid as a psychic energizer. Amer. Psychiat.Assoc. Psychiat. Research Rept., 8: 129-135, 1957.

2. Voelkel, A.: Clinical experiences with amineoxidase inhibitors in psychiatry. Ann. N.Y. Acad.Sci., 80:680-686, 1959.

3. Pletscher, A.: Significance of monoamine oxidaseinhibition for the pharmacological and clinicaleffects of hydrazine derivatives. Ann. N.Y. Acad.Sci., 80:1039-1045, 1959.

4. Saunders, J. C., Randinger, N., Rochlin, D. andKline, N. S.: Treatment of depressed patientswith iproniazid and reserpine. Dis. Nerv. Syst.,20( 1) :31-39, 1959.

5. Zeller, E. A.: Some remarks about monoamineoxidase and monoamine oxidase inhibitors. J.Neuropsychiat., 2: 125-130, 1960-1961.

6. Resnick, 0.: The influence of amine oxidase in­hibitors on epinephrine metabolism in man.Ann. N. Y. Acad. Sci., 80:726-733, 1959.

7. Resnick, 0., Hagopian, M., Hoagland, H. andFreeman, H.: An in vivo test for measuringmonoamine oxidase inhibition in human subjects.A.M.A. Arch. Gen. Psychiat., 2:459-461, 1960.

8. Feldstein, A., Hoagland, H., Rivera, M. andFreeman, H.: A preliminary report on MAO in­hibition and clinical effectiveness in the treat­ment of depressed patients with phenelzine. ].Neuropsychiat., 2: 12-14, 1960.

9. Gylys, J. A., Muccia, P. M. R. and Taylor, M. K.:Pharmacological and toxicological properties of2-methyl-3-piperidinopyrazine, a new antide­pressant. Ann. N. Y. Acad. Sci., 107:899-913,1963.

10. Dubnick, B., Morgan, F. and Phillips, G. E.: In­hibition of monoamine oxidase by 2-methyl-3­piperidinopyrazine. Ann. N. Y. Acad. Sci., 107:914-923, 1963.

ll. Goldstein, L., Murphree, H. B. and Pfeiffer, C.C.: Quantitative electroencephalography in manas a measure of CNS stimulation. Ann. N. Y.Acad. Sci., 107:1045-1056, 1963.

12. Dunlop, E.: Antidepressant effects of MAO in­hibitors. Ann. N. Y. Acad. Sci., 107:1107-1116,1963.

13. Feldman, P.: Comparison of effect of 2-methyl­3-piperidinopyrazine on target symptoms of an­ergic schizophrenics. Ann. N. Y. Acad. Sci.,107:1117-1130, 1963.

14. Hamilton, M.: A rating scale for depression. ].Neurol. Neurosurg. and Psychiat., 23:56-62,1960.

15. Sjoerdsma, A., Oates, J. A., Zaltzman, P., andUndenfriend, S.: Identification and assay ofurinary tryptamine: application as an index ofmonoamine oxidase inhibition in man. J. Phar­macol. and Exper. Therap., 126:217-223, 1959.

16. Pisano, J. J., Crout, J. R. and Abraham, D.:Determination of 3-methoxy-4-hydroxymandelicacid in urine. Clin. Chemica. Acta., 7 :285-291,1962.

17. Undenfriend, S., Titus, E. and Weissbach, H.:The identification of 5-hydroxy-3-indoleaceticacid in normal urine and method for its assay.J.B.C., 216:499-505, 1955.

(Doctor Dunlop)Fuller Memorial SanitariumAttleboro, Massachusetts

"The average practitioner is quite capable of handling the vast majority of ex-institutionalizedpatients by regulation of medication, reassurance, manipulation of the environment wherenecessary, and ... other technics."

-N. S. KLINE, Postgrad. Med.,27:620, May, 1960.

ERRATUMIn the Editorial of the November-December 1964 issue the editor noted that "Psychoso­

matics has now completed its fourth year." This is an understatement of the true facts; sincepublication was commenced in January, 1960; it is therefore corrected to "its fifth year.' Theeditor cannot and will not seek refuge in the possibility of an error that can be traced to hisassistant, nor to the publisher. The best explanation is either that 1960-1964 is a span of fouryears, or hopefully that it is a significant slip indicating his continued interest in the journaland the fact that another year or less is not too significant. WD

January-February, 1965.,.•